Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial
| Autor: | Ajith M. Joseph, Yair Lotan, Daniel J. Canter, Wassim Kassouf, Susan Jewell, Leah G. Davis, Siamak Daneshmand, Edward M. Messing, Brant A. Inman, Stephen A. Boorjian, H. Tony Marble |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty Urology 030232 urology & nephrology Disease In situ hybridization Single Center 03 medical and health sciences 0302 clinical medicine Adjuvants Immunologic Internal medicine Multicenter trial medicine Humans Neoplasm Invasiveness Prospective Studies In Situ Hybridization Fluorescence Aged Neoplasm Staging Bladder cancer medicine.diagnostic_test business.industry Incidence Carcinoma in situ Cystoscopy medicine.disease United States Survival Rate Administration Intravesical Urinary Bladder Neoplasms BCG Vaccine Disease Progression Female Neoplasm Recurrence Local business BCG vaccine Carcinoma in Situ Fluorescence in situ hybridization |
| Zdroj: | Journal of Urology. 202:920-926 |
| ISSN: | 1527-3792 0022-5347 |
| Popis: | Single center studies have shown that positive UroVysion® fluorescence in situ hybridization results were associated with recurrence of nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. Our goal was to validate these findings.We performed a prospective, multicenter diagnostic trial to determine whether the fluorescence in situ hybridization test could predict recurrence or progression in patients with primary high grade nonmuscle invasive bladder cancer who were scheduled to receive bacillus Calmette-Guérin. Fluorescence in situ hybridization testing was performed prior to the first bacillus Calmette-Guérin instillation, prior to the sixth instillation and at 3-month cystoscopy. The performance of fluorescence in situ hybridization was evaluated.A total of 150 patients were enrolled in analysis, including 68 with Ta disease, 41 with T1 disease, 26 with carcinoma in situ alone and 15 with papillary carcinoma plus carcinoma in situ. At 9 months of followup there were 46 events, including 37 recurrences and 9 progressions. For events with positive fluorescence in situ hybridization findings the HR was 2.59 (95% CI 1.42-4.73) for the baseline test, 1.94 (95% CI 1.04-3.59) for the 6-week test and 3.22 (95% CI 1.65-6.27) at 3 months. Patients with positive results at baseline, 6 weeks and 3 months had events 55% of the time and patients with negative results at each time point had no event 76% of the time.The study validated that a positive UroVysion fluorescence in situ hybridization test was associated with a 3.3-fold increased risk of recurrence. The test may be useful to risk stratify patients entering clinical trials in whom induction therapy fails. However, using the test to change management decisions is limited due to the discordance between results and outcomes as well as the variance of tests results with time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|